0.0454CHF-1.30%Mkt Cap: 6.90M CHFP/E: —Last update: 2026-06-01
Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for neurological disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enz…
Industry Peers
Biotechnology111.39BUSDP/E 26.0
100.62BDKKP/E 19.4
62.97BUSDP/E 14.7
48.39BEURP/E 31.7
44.65BEURP/E 37.2
40.10BUSDP/E 75.3
35.22BUSD—
32.91BSEKP/E 48.6
Indicators:|
Key Statistics
Company
Market Cap6.90M CHF
Enterprise Value3.21M CHF
Revenue (TTM)173.00K CHF
Gross Profit-499.00K CHF
Net Income (TTM)-6.73M CHF
Revenue/Share0.0020 CHF
Last Price0.0454 CHF
Fiscal Year EndDec 2025
MR QuarterDec 2025
Employees—
CountryCH
SectorHealthcare
IndustryBiotechnology
ISINCH0029850754
Valuation
P/E (Trailing)—
P/E (Forward)-1.15
PEG—
EV/EBITDA-1.14
EV/Revenue18.56
P/S40.39
P/B0.90
EPS (TTM)-0.06
EPS (Forward)-0.04
52W Range
0.033623% of range0.0850
52W High0.0850 CHF
52W Low0.0336 CHF
Profitability
Gross Margin-288.44%
Oper. Margin-4882.06%
EBITDA Margin0.00%
Profit Margin-22448.44%
ROE-141.15%
ROA-105.72%
Growth
Revenue Growth959.00%
Earnings Growth—
Cash Flow & Leverage
Operating CF-2.17M CHF
CapEx (TTM)—
FCF Margin—
FCF Yield—
Net Debt-2.15M CHF
Net Debt/EBITDA0.76
Balance Sheet
Debt/Equity0.01
Current Ratio—
Quick Ratio—
Book Value/Sh0.0510 CHF
Cash/Share0.0190 CHF
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 CHF
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay DateJul 26, 2022
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.151.90M
Float92.72M
Insiders10.00%
Institutions1.12%
Technical
SMA 500.0448 (+1.2%)
SMA 2000.0535 (-15.2%)
Beta1.98
S&P 52W Chg27.70%
Avg Vol (30d)236.08K
Avg Vol (10d)216.66K
Technical Indicators
RSI (14)49.2
MACD0.0000
MACD Signal0.0002
MACD Hist.-0.0002
BB Upper0.0496 CHF
BB Middle0.0468 CHF
BB Lower0.0440 CHF
BB Width11.96%
ATR (14)0.0039 CHF
Vol Ratio (20d)0.29x